# VasoNova

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vasonova

- Industry: Medical Devices & Equipment
- Headquarters: Menlo Park, US
- Website: www.vasonova.com
- Total disclosed funding: $11M
- Latest round: Series B (Sep 16, 2008)
- Investors on record: 7

## About

VasoNova specializes in developing innovative medical solutions focused on enhancing vascular procedures, particularly in central venous catheter placements with their advanced technologies.VasoNova, founded in 2005 in Menlo Park, US, focuses on vascular positioning systems. The firm was acquired by Teleflex in January 2011, enhancing its resources and market presence. Sukhtej D, the founder, has a history of leading ventures in medical technology. The company has participated in 5 deals, raising a total of USD 10.00 mn, with its latest funding being a VENTURE DEBT round of USD 2.24 mn.VasoNova offers advanced medical devices, notably the Arrow® VPS G4™ Vascular Positioning System. This device improves the accuracy and efficiency of central venous catheter placements by enabling precise tip confirmation and facilitating optimal catheter positioning, especially in urgent clinical settings. Its primary customers include hospitals and clinics in the US and Canada, with opportunities for international expansion as demand for effective catheter solutions increases.VasoNova generates revenue through direct sales of its medical devices, including the Arrow® VPS G4™ Device, targeting healthcare institutions via a B2B model. Their revenue streams also include pre-loaded Arrowg+ard Blue Advance™ PICCs which are compatible with the VPS G4™ Device, and they are likely engaged with medical supply distributors to broaden their market reach, aligning their pricing with the competitive landscape of advanced medical devices.VasoNova is focused on expanding its product line and geographic reach. Recent developments include enhancements to their existing vascular positioning technology and potential new product launches aimed for 2023. The company is set to target growth in international markets, particularly Europe and Asia, within the next two years. The funding raised from the VENTURE DEBT round in January 2011 will support these initiatives, aiding in product development and market entry strategies.

## Funding rounds

- Series B, Sep 16, 2008, $10M — Presidio Partners, California Technology Ventures, Research Corporation Technologies, Aphelion Capital, Arboretum Ventures
- Series A, Mar 6, 2007, $1.3M — Aphelion Capital, Life Science Angels, Inc., Coronis Medical Ventures

## Investors

- Aphelion Capital (https://capitalatlas.ai/funds/aphelion-capital) — Series A, Series B
- Life Science Angels, Inc. — Series A
- Coronis Medical Ventures — Series A
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series B
- California Technology Ventures (https://capitalatlas.ai/funds/california-technology-ventures) — Series B
- Research Corporation Technologies (https://capitalatlas.ai/funds/research-corporation-technologies) — Series B
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series B